Immunotherapy against several tumors including gastrointestinal and gastric cancer
A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
1. A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide consists of the amino acid sequence of LYQILQGIVF (SEQ ID NO: 1), wherein the peptide is in a complex with an MHC molecule.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , further comprising expanding T cells in vitro.
6. The method of claim 1 , wherein the MHC molecule is a class I molecule.
7. The method of claim 1 , wherein the composition further comprises an adjuvant.
8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
9. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
10. The method of claim 9 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells.
11. The method of claim 1 , wherein the patient has gastric cancer.
12. The method of claim 1 , wherein the patient has gastrointestinal cancer.
13. The method of claim 1 , wherein the patient has colorectal cancer.
14. The method of claim 1 , wherein the patient has pancreatic cancer.
15. The method of claim 1 , wherein the MEW molecule is HLA-A*024.